Clinical Trials in the Netherlands / NCT07558174
Recruiting
Observational
SPECTATOR: Perfusion Monitoring Before, During and After Lower Extremity Revascularization With Laser Speckle Contrast Imaging
NCT07558174 · tracked via the Priya Life Science Netherlands tracker
Condition(s) studied
Vascular Disease,Peripheral
Investigational drug(s) / intervention(s)
Laser Speckle Contrast Imaging
Laser Speckle Contrast Imaging: Measurement with LSCI device
Study summary
This study aims to evaluate the feasibility of Laser Speckle Contrast Imaging for perioperative perfusion assessment of the lower extremity before, during, and after revascularization.
Eligibility
Inclusion Criteria:
* Scheduled for lower-extremity revascularization
* Undergoing pre- and postoperative indocyanine near-infrared fluorescence perfusion measurements
Exclusion Criteria:
Any condition that the investigator considers to be potentially jeopardizing the patient's wellbeing or the study objectives
Primary outcome measure(s)
- To assess the feasibility and the quantification of laser speckle contrast imaging for monitoring of perfusion of the lower extremities during and following revascularization — Up to 48 hours (from pre-operative baseline measurement to the final postoperative measurement, performed on the same day for PTA procedures or on postoperative day 1 for bypass and TEA procedures)
Feasibility
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Leiden University Medical Center | Leiden | South Holland | Recruiting |
More Leiden University Medical Center trials in the Netherlands
The NEU-STIM Trial
Recruiting
PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer
Active, not recruiting
Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy
Active, not recruiting
Repeated GON Injections in CCH
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07558174 on ClinicalTrials.gov ↗ ← All trials in the Netherlands